CD34 and non-Hodgkin lymphoma: Autologous hematopoietic cell (HC) transplantation is widely applied to reconstitute hematopoiesis after high-dose chemotherapy in patients with hematologic malignancies including multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), and Hodgkin's lymphoma.1,2 Mobilized peripheral blood (PB) CD34+ hematopoietic stem and progenitor cells (HSPCs) are easy to collect, have a high engraftment potential, and are used as preferred source for transplantation.